KEY market INSIGHTS ? PRESENTLY, OVER 220 CANDIDATES ARE CURRENTLY BEING EVALUATED ACROSS DIFFERENT STAGES OF CLINICAL DEVELOPMENT AND NINE BISPECIFIC ANTIBODY THERAPEUTICS HAVE BEEN COMMERCIALIZED ? OVER 180 CANDIDATES ARE CURRENTLY UNDER PRECLINICAL STUDIES AND OVER 30% OF SUCH CANDIDATES ARE CURRENTLY BEING EVALUATED UNDER IND STUDIES ? MORE THAN 120 PLAYERS CURRENTLY CLAIM TO BE ENGAGED IN THE BISPECIFIC ANTIBODY THERAPEUTICS DOMAIN ? OVER 70 BISPECIFIC ANTIBODY THERAPEUTICS ARE BEING DEVELOPED BY BIG PHARMA PLAYERS, ACROSS THE GLOBE ? NEARLY 35% OF CAGR WAS WITNESSED IN THE PARTNERSHIP ACTIVITY IN THIS MARKET, IN THE PAST SEVEN YEARS ? MORE THAN 37,000 PATIENTS HAVE BEEN ENROLLED IN CLOSE TO 280 CLINICAL TRIALS, BEING CONDUCTED ACROSS THE GLOBE ? OVER 60% OF THE PROJECTED BISPECIFIC ANTIBODY MARKET OPPORTUNITY IN THIS DOMAIN, IN 2035, IS ANTICIPATED TO BE CAPTURED BY PLAYERS BASED IN NORTH AMERICA TABLE OF CONTENTS 1. PREFACE 1.1. INTRODUCTION 1.2. KEY MARKET INSIGHTS 1.3. SCOPE OF THE REPORT 1.4. RESEARCH METHODOLOGY 1.5. FREQUENTLY ASKED QUESTIONS 1.6. CHAPTER OUTLINES 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. CHAPTER OVERVIEW 3.2. INTRODUCTION TO ANTIBODIES 3.3. ANTIBODY THERAPEUTICS 3.4. BISPECIFIC ANTIBODY FORMATS 3.5. MECHANISM OF ACTION OF BISPECIFIC ANTIBODY THERAPEUTICS OTHER MECHANISMS 3.6. APPLICATIONS OF BISPECIFIC ANTIBODIES 4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES 4.1. CHAPTER OVERVIEW 4.2. APPROVED AND CLINICAL BISPECIFIC ANTIBODY THERAPEUTICS: OVERALL MARKET LANDSCAPE 4.3. APPROVED AND CLINICAL BISPECIFIC ANTIBODY THERAPEUTICS: OVERALL DEVELOPER LANDSCAPE 5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES 5.1. CHAPTER OVERVIEW 5.2. PRECLINICAL BISPECIFIC ANTIBODY THERAPEUTICS: OVERALL MARKET LANDSCAPE 5.3. PRECLINICAL BISPECIFIC ANTIBODY THERAPEUTICS: OVERALL DEVELOPER LANDSCAPE 6. KEY INSIGHTS 6.1. CHAPTER OVERVIEW 6.2. APPROVED AND CLINICAL STAGE BISPECIFIC ANTIBODY THERAPEUTICS LANDSCAPE: KEY INSIGHTS 6.3. PRECLINICAL STAGE BISPECIFIC ANTIBODY THERAPEUTICS LANDSCAPE: KEY INSIGHTS 6.4. BISPECIFIC ANTIBODY THERAPEUTIC DEVELOPERS LANDSCAPE: KEY INSIGHTS 7. TECHNOLOGY ASSESSMENT FRAMEWORK 7.1. CHAPTER OVERVIEW 7.2. BISPECIFIC ANTIBODY THERAPEUTICS: LIST OF TECHNOLOGY PLATFORMS 7.3. BISPECIFIC ANTIBODY TECHNOLOGY PLATFORMS: COMPARATIVE ANALYSIS 8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS 8.1. CHAPTER OVERVIEW 8.2. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS (SPIDER WEB REPRESENTATION) 8.3. BIG PHARMA PLAYERS: COMPARATIVE CLINICAL PIPELINE ANALYSIS 9. COMPANY PROFILES 9.1. CHAPTER OVERVIEW 9.2. AKESO BIOPHARMA 9.2.1. COMPANY OVERVIEW 9.2.2. FINANCIAL PERFORMANCE 9.2.3. DRUG PORTFOLIO 9.2.4. RECENT DEVELOPMENTS AND FUTURE OUTLOOK 9.3. ALPHAMAB ONCOLOGY 9.4. AMGEN 9.5. MERCK 9.6. REGENERON 9.7. ROCHE 9.8. XENCOR 10. PARTNERSHIPS AND COLLABORATIONS 10.1. CHAPTER OVERVIEW 10.2. PARTNERSHIP MODELS 10.3. BISPECIFIC ANTIBODY THERAPEUTICS: PARTNERSHIPS AND COLLABORATIONS 11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS 11.1. CHAPTER OVERVIEW 11.2. MANUFACTURING OF BISPECIFIC ANTIBODY THERAPEUTICS 11.3. KEY CONSIDERATIONS FOR SELECTING A SUITABLE CMO / CRO PARTNER 12. CLINICAL TRIAL ANALYSIS 12.1. CHAPTER OVERVIEW 12.2. KEY ASSUMPTIONS AND METHODOLOGY 12.3. BISPECIFIC ANTIBODY THERAPEUTICS: CLINICAL TRIAL ANALYSIS 13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES 13.1. CHAPTER OVERVIEW 13.2. GUIDELINES ISSUED BY REGULATORY AUTHORITIES 14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES 14.1. CHAPTER OVERVIEW 14.2. KEY CHANNELS USED FOR PROMOTIONAL CAMPAIGNS 14.3. OTHER CHANNELS USED FOR PROMOTIONAL AND MARKETING STRATEGIES 14.4. SUMMARY: PROMOTIONAL AND MARKETING STRATEGY LEVERAGED BY BISPECIFIC ANTIBODY DEVELOPERS 14.5. PROMOTIONAL ANALYSIS: BLINCYTO™ 14.6. PROMOTIONAL ANALYSIS: HEMLIBRA® 15. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15.1. CHAPTER OVERVIEW 15.2. SCOPE AND LIMITATIONS 15.3. FORECAST METHODOLOGY AND KEY ASSUMPTIONS 15.4. BISPECIFIC ANTIBODY THERAPEUTICS MARKET, 2023-2035 15.5. BISPECIFIC ANTIBODY MARKET: VALUE CREATION ANALYSIS 15.6. BISPECIFIC ANTIBODY THERAPEUTICS MARKET: PRODUCT-WISE SALES FORECASTS 15.7. CONCLUDING REMARKS 16. SWOT ANALYSIS 16.1. CHAPTER OVERVIEW 16.2. STRENGTHS 16.3. WEAKNESSES 16.4. OPPORTUNITIES 16.5. THREATS 16.6. CONCLUDING REMARKS 17. CONCLUDING REMARKS 18. EXECUTIVE INSIGHTS 18.1. CHAPTER OVERVIEW 18.2. IMMUNAI 18.3. UNIVERSITY OF FREIBURG 18.4. SYNIMMUNE 18.5. CYTOMX THERAPEUTICS 18.6. F-STAR 18.7. INNOVENT BIOLOGICS 19. APPENDIX 1: TABULATED DATA 20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION TO VIEW MORE DETAILS ON THIS REPORT, CLICK ON THE LINK HTTPS://WWW.ROOTSANALYSIS.COM/REPORTS/VIEW_DOCUMENT/BISPECIFIC-ANTIBODIES/286.HTML LEARN FROM EXPERTS: DO YOU KNOW ABOUT THESE EMERGING INDUSTRY TRENDS? TOP 10 CELL AND GENE THERAPY COMPANIES TOP 5 COMPANIES DEVELOPING BISPECIFIC ANTIBODIES ABOUT ROOTS ANALYSIS ROOTS ANALYSIS IS A GLOBAL LEADER IN THE PHARMA / BIOTECH MARKET RESEARCH. HAVING WORKED WITH OVER 750 CLIENTS WORLDWIDE, INCLUDING FORTUNE 500 COMPANIES, START-UPS, ACADEMIA, VENTURE CAPITALISTS AND STRATEGIC INVESTORS FOR MORE THAN A DECADE, WE OFFER A HIGHLY ANALYTICAL / DATA-DRIVEN PERSPECTIVE TO A NETWORK OF OVER 450,000 SENIOR INDUSTRY STAKEHOLDERS LOOKING FOR CREDIBLE MARKET INSIGHTS. LEARN MORE ABOUT ROOTS ANALYSIS CONSULTING SERVICES: CONNECT WITH OUR ROOTS ANALYSIS CONSULTING TEAM: FOR YOUR CUSTOM RESEARCH EXCLUSIVE BEST-IN-CLASS QUALITY PROJECTS CONTACT: BEN JOHNSON +1 (415) 800 3415 BEN.JOHNSON@ROOTSANALYSIS.COM